Clinical Trials Logo

CKD clinical trials

View clinical trials related to CKD.

Filter by:

NCT ID: NCT06279429 Recruiting - Sleep Disorder Clinical Trials

Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia

Start date: May 31, 2022
Phase: N/A
Study type: Interventional

Insomnia or sleep disturbance is a common disorder in patients with chronic kidney disease (CKD), but is often unrecognized and undertreated. It is known that sleep disorders may indirectly cause a variety of diseases and affect quality of life. The most common sleep disorders that occur in CKD are insomnia, excessive daytime sleepiness, obstructive or central sleep apnea (SA), and sleep disorders. This study evaluates the effectiveness and safety of Sideral® Sucrosomial Iron and iron chewable tablets 100mg commonly used in health insurance on sleep disorders in patients with CKD and iron deficiency anemia.

NCT ID: NCT06237712 Enrolling by invitation - CKD Clinical Trials

Explorative Study to Investigate the Acid-base Response to Sodium and Potassium Salts in Patients With Chronic Kidney Disease.

5S
Start date: January 26, 2024
Phase: N/A
Study type: Interventional

With this research the investigators want to study how patients with chronic kidney disease respond to different sodium- and potassium salts. Potassium salts can prevent kidney damage and cardiovascular disease, however patients with chronic kidney disease can responds differently. Extra potassium can increase the amount of potassium in the blood and extra chloride can cause acidosis. With this study the investigators will gain more insight in how patients with chronic kidney disease respond to sodium and potassium salts and which one is more favorable.This information can then be used to guide the application of salt substitutes and dietary adjustments in patients with chronic kidney disease.

NCT ID: NCT06189807 Recruiting - Clinical trials for Chronic Kidney Diseases

Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)

PACE-CKD
Start date: February 14, 2024
Phase: N/A
Study type: Interventional

This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.

NCT ID: NCT06143098 Not yet recruiting - CKD Clinical Trials

Some Hematological Profile in Children With Chronic Kidney Disease

Start date: March 1, 2024
Phase:
Study type: Observational

This study is asses the hematological changes in children with chronic kidney disease stage 3 to 5 including - Complete blood picture - Coagulation profile (PT, PC, PTT) - Iron study

NCT ID: NCT06094920 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Optimize@Home
Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria. The main questions it aims to answer are: - What is the feasibility (and advantages) of remote clinical trial conduct with multiple medications in patients with type 2 diabetes and elevated albuminuria? - What is the individual response to the SGLT2 inhibitor empagliflozin in urine albumin-creatinine ratio? - What is the individual response to the SGLT2 inhibitor empagliflozin in systolic blood pressure, body weight, eGFR, and fasting plasma glucose? - Can suboptimal treatment responses to empagliflozin be overcome by the addition or substitution with finerenone? Participants will collect all study data in the comfort of their own environments - First-morning void urine samples - Capillary blood samples - Blood pressure - Body weight Participants will be assigned to a 3-week treatment period with empagliflozin 10 mg/day. Based on the albuminuria response after 2 weeks, participants will be allocated to one of three treatment regimens after the 3-week treatment period with empagliflozin: - Continue empagliflozin for 4 more weeks (good response). - Continue empagliflozin for 4 more weeks and add finerenone 10 or 20 mg will be added for 4 weeks (moderate response). - Stop empagliflozin and start finerenone 10 or 20 mg for 4 weeks (no response)

NCT ID: NCT06072287 Recruiting - Obesity Clinical Trials

The Living With a Long-Term Condition Study

LTC
Start date: June 28, 2023
Phase:
Study type: Observational

Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs). Being able to measure whether psychological distress is related to living with a LTC would allow researchers and clinicians to provide interventions specifically tailored to the challenges of living with a LTC and therefore provide the most appropriate support for these patients. Such a measure would also be useful in research to identify the presence of illness-related distress in different patient groups. This project will therefore create a new measure of illness-related distress that has applications for both research and clinical practice. This will involve the psychometric validation of the new illness-related distress measure to test how valid and reliable the measure is. The aim of the project is to provide initial validation of the Illness Related Distress Scale in a community sample, recruited through online platforms. The objective of the study is to gather initial validity and reliability data for the scale.

NCT ID: NCT06009250 Not yet recruiting - NAFLD Clinical Trials

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut

Start date: December 2023
Phase:
Study type: Observational

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question[s] it aims to answer are: - [question 1] prevalence of NAFLD in CKD patients. - [question 2] the relationship between NAFLD and CKD.

NCT ID: NCT05970094 Completed - Kidney Diseases Clinical Trials

Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5

REMA-CKD
Start date: March 6, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about and test the effect of an acid/base diet, in chronic kidney patients with CKD stage 4 and 5 in an interventional study with a historical control. The hypothesize is, that an acid/base diet will reduce the degree of acidosis and the need for oral bicarbonate supplements.

NCT ID: NCT05936151 Recruiting - Type 2 Diabetes Clinical Trials

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Start date: July 20, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

NCT ID: NCT05934552 Not yet recruiting - CKD Clinical Trials

Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients

Start date: December 2023
Phase:
Study type: Observational

Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters of CKD as GFR, UREA ,CREATININE, CLINICAL and UREMIC assessment (lower limb edema ,UOP,base of chest ,vomiting ,dyspnea,blood pressure measurement)